R105
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 6
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.400
- MYC_TARGETS_V1+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- G2M_CHECKPOINT+0.350
- MYC_TARGETS_V2+0.240
- SPERMATOGENESIS+0.220
- FATTY_ACID_METABOLISM+0.190
- UNFOLDED_PROTEIN_RESPONSE+0.190
- ALLOGRAFT_REJECTION+0.180
- ANDROGEN_RESPONSE+0.150
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- WNT_BETA_CATENIN_SIGNALING-0.380
- P53_PATHWAY-0.370
- TGF_BETA_SIGNALING-0.360
- APICAL_JUNCTION-0.340
- MYOGENESIS-0.340
- PI3K_AKT_MTOR_SIGNALING-0.310
- HYPOXIA-0.300
- ANGIOGENESIS-0.280
- APOPTOSIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-44-3917-01A-01R-A278-07 | — | cohortMD2 | 0.801 |
| 2 | TCGA-E7-A85H-01A-11R-A352-07 | — | — | 0.794 |
| 3 | SRR11296797 | — | — | 0.793 |
| 4 | 98e3beb5-bff2-4c4e-b492-c4ed7dda9d9c | — | — | 0.789 |
| 5 | TCGA-69-8255-01A-11R-2287-07 | — | cohortA4 | 0.786 |
| 6 | SRR11296733 | — | — | 0.776 |
| 7 | c94686d5.355c.432f.bc98.ccdd30a209de | — | cohortA4 | 0.773 |
| 8 | TCGA-22-4613-01A-01R-1443-07 | — | cohortSQ2 | 0.773 |
| 9 | TCGA-CV-6948-01A-11R-1915-07 | — | — | 0.772 |
| 10 | SRR8518141 | — | E | 0.765 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.180 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.020 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.010 | Inavolisib | — uncovered |